Literature DB >> 22399285

Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.

V N P Le1, T H Hoang Thi, E Robins, M P Flament.   

Abstract

Interactions between particles are dependent on the physicochemical characteristics of the interacting particles but it is also important to consider the manufacturing process. Blending active pharmaceutical ingredient (API) with carrier is a critical stage that determines the blend homogeneity and is the first step towards obtaining the final quality of the powder blend. The aim of this work was to study parameters that influence the interactions between API and carrier in adhesive mixtures used in DPI and their effect on API dispersion. The study was done with fluticasone propionate blended with lactose 'Lactohale 200'. The study was based on the influence of the operating conditions (speed, mixing time, resting steps during mixing), the size of the carrier and the storage conditions on the blend properties and on the API dispersion. The quality of the blends was examined by analysing the API content uniformity. Adhesion characteristics were evaluated by submitting mixtures to a sieving action by air depression with the Alpine air-jet sieve. Aerodynamic evaluation of fine particle fraction (FPF) was obtained using a Twin Stage Impinger; the FPF being defined as the mass percentage of API below 6.4 μm. For good dispersion and therefore good homogeneity of the API in the carrier particles, speed and powder blending time have to be sufficient, but not too long to prevent the appearance of static electricity, which is not favourable to homogeneity and stability. The FPF increases with the decrease in the carrier size. The storage conditions have also to be taken into consideration. Higher humidity favours the adhesion of API on the carrier and decreases the FPF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399285      PMCID: PMC3364368          DOI: 10.1208/s12249-012-9765-8

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  21 in total

1.  Influence of carrier on the performance of dry powder inhalers.

Authors:  G Saint-Lorant; P Leterme; A Gayot; M P Flament
Journal:  Int J Pharm       Date:  2006-10-21       Impact factor: 5.875

2.  Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation.

Authors:  Handoko Adi; Ian Larson; Herbert Chiou; Paul Young; Daniela Traini; Peter Stewart
Journal:  Pharm Res       Date:  2006-09-14       Impact factor: 4.200

Review 3.  The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors:  Matthew D Jones; Robert Price
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

4.  Drug agglomeration and dissolution--what is the influence of powder mixing?

Authors:  Kamakshi Kale; Karen Hapgood; Peter Stewart
Journal:  Eur J Pharm Biopharm       Date:  2009-05       Impact factor: 5.571

5.  Effects of electrostatic charging on pharmaceutical powder blending homogeneity.

Authors:  Yu Pu; Malay Mazumder; Charles Cooney
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

6.  The effect of blending time on particle adhesion in a model interactive system.

Authors:  P Kulvanich; P J Stewart
Journal:  J Pharm Pharmacol       Date:  1987-09       Impact factor: 3.765

7.  Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.

Authors:  X M Zeng; G P Martin; S K Tee; A A Ghoush; C Marriott
Journal:  Int J Pharm       Date:  1999-05-25       Impact factor: 5.875

8.  Electrostatic characterisation of inhaled powders: effect of contact surface and relative humidity.

Authors:  Abdulmagid Elajnaf; Paul Carter; Geoff Rowley
Journal:  Eur J Pharm Sci       Date:  2006-07-28       Impact factor: 4.384

9.  Measurement of electrostatic charge decay in pharmaceutical powders and polymer materials used in dry powder inhaler devices.

Authors:  P A Carter; G Rowley; E J Fletcher; V Stylianopoulos
Journal:  Drug Dev Ind Pharm       Date:  1998-11       Impact factor: 3.225

10.  The effects of high shear blending on alpha-lactose monohydrate.

Authors:  R H Bridson; P T Robbins; Y Chen; D Westerman; C R Gillham; T C Roche; J P K Seville
Journal:  Int J Pharm       Date:  2007-02-23       Impact factor: 5.875

View more
  7 in total

1.  Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

2.  Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial Hypertension.

Authors:  Shalaleh Zendehdel Baher; Shadi Yaqoubi; Kofi Asare-Addo; Hamed Hamishehkar; Ali Nokhodchi
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

3.  Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-10-16       Impact factor: 4.200

4.  Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size.

Authors:  Ping Du; Ju Du; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-06-25       Impact factor: 3.246

5.  Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres.

Authors:  Waseem Kaialy; Tariq Hussain; Amjad Alhalaweh; Ali Nokhodchi
Journal:  Pharm Res       Date:  2013-08-06       Impact factor: 4.200

Review 6.  Influence of physical properties of carrier on the performance of dry powder inhalers.

Authors:  Tingting Peng; Shiqi Lin; Boyi Niu; Xinyi Wang; Ying Huang; Xuejuan Zhang; Ge Li; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2016-05-04       Impact factor: 11.413

7.  Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Authors:  Kai-Michael Beeh; Anne-Marie Kirsten; Daniel Dusser; Ashish Sharma; Piet Cornelissen; Ralf Sigmund; Petra Moroni-Zentgraf; Ronald Dahl
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-09       Impact factor: 2.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.